Verde Science, Inc. announced that along with some renowned research scientists it intends to study the treatment potential of a cannabis preparation (Nabiximols) in the treatment of Huntingdon's Disease as a sponsor at 2 universities in North America. The study as currently designed will be a double-blind, placebo controlled protocol with 48 subjects.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2021 | Verde Science : Two more UK energy suppliers stop trading on gas price hit | RE |
2018 | Verde Science, Inc. Announces Executive Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 23 | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.67% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- VRCI Stock
- News Verde Science, Inc.
- Verde Science, Inc. Announces Plan to Study Cannabis Preparation for Treatment of Huntingdon's Disease